Register
Autoinjectable testosterone now available for the first time |
Journal Updates
eMediNexus Coverage from: 
Autoinjectable testosterone now available for the first time

0 Read Comments                

The US Food and Drug Administration (FDA) has approved testosterone enanthate (Xyosted, Antares Pharma) subcutaneous injection (50 mg, 75 mg, and 100 mg) for testosterone replacement therapy in men diagnosed with conditions associated with a deficiency or absence of endogenous testosterone. It is the first FDA-approved subcutaneous testosterone enanthate product for once-weekly self-administration using a disposable autoinjector.

To comment on this article,
create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies
Create Account

Already registered?

Login Now